Matteo Bassetti to Treatment Outcome
This is a "connection" page, showing publications Matteo Bassetti has written about Treatment Outcome.
Connection Strength
0.402
-
Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med. 2021 08; 15(8):985-992.
Score: 0.034
-
Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. BMC Infect Dis. 2021 Apr 15; 21(1):353.
Score: 0.034
-
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS One. 2020; 15(8):e0237831.
Score: 0.032
-
High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. Eur J Clin Invest. 2020 Oct; 50(10):e13358.
Score: 0.032
-
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr; 53(4):408-415.
Score: 0.028
-
Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol. 2018 08; 13:1081-1094.
Score: 0.027
-
The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis. 2018 04; 31(2):141-147.
Score: 0.027
-
When to switch to an oral treatment and/or to discharge a patient with skin and soft tissue infections. Curr Opin Infect Dis. 2018 04; 31(2):163-169.
Score: 0.027
-
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. J Neurovirol. 2017 12; 23(6):908-912.
Score: 0.026
-
Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. Minerva Anestesiol. 2017 11; 83(11):1126-1136.
Score: 0.026
-
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. J Glob Antimicrob Resist. 2017 06; 9:100-102.
Score: 0.026
-
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017 Feb; 49(2):255-258.
Score: 0.025
-
Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit Care. 2021 03 19; 25(1):111.
Score: 0.008
-
Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission. Nutrition. 2021 09; 89:111236.
Score: 0.008
-
Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia. Crit Care. 2021 02 24; 25(1):81.
Score: 0.008
-
Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients? AIDS. 2020 10 01; 34(12):1865-1867.
Score: 0.008
-
Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clin Infect Dis. 2019 11 13; 69(11):1912-1918.
Score: 0.008
-
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018 Feb; 51(2):244-248.
Score: 0.007
-
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses. 2017 Oct; 60(10):663-667.
Score: 0.006
-
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection. 2008 Aug; 36(4):358-61.
Score: 0.003